Premium
Non‐subtype‐selective opioid receptor antagonism in treatment of levodopa‐induced motor complications in Parkinson's disease
Author(s) -
Fox Susan,
Silverdale Montague,
Kellett Mark,
Davies Rhys,
Steiger Malcolm,
Fletcher Nicholas,
Crossman Alan,
Brotchie Jonathan
Publication year - 2004
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.10693
Subject(s) - antagonism , levodopa , parkinson's disease , medicine , opioid , disease , degenerative disease , pharmacology , neuroscience , receptor , psychology
Opioid peptide transmission is enhanced in the striatum of animal models and Parkinson's disease (PD) patients with levodopa‐induced motor complications. Opioid receptor antagonists reduce levodopa‐induced dyskinesia in primate models of PD; however, clinical trials to date have been inconclusive. A double‐blind, placebo controlled, crossover design study in 14 patients with PD experiencing motor fluctuations was carried out, using the non‐subtype‐selective opioid receptor antagonist naloxone. Naloxone did not reduce levodopa‐induced dyskinesia. The duration of action of levodopa was increased significantly by 17.5%. Non‐subtype‐selective opioid receptor antagonism may prove useful in the treatment of levodopa‐related wearing‐off in PD but not in dyskinesia. © 2003 Movement Disorder Society